Korean J Intern Med.
2016 Mar;31(2):406-408. 10.3904/kjim.2014.353.
Mixed-phenotype acute leukemia treated with decitabine
- Affiliations
-
- 1Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea. wonsik112@gmail.com
- 2Department of Laboratory Medicine, Inje University Busan Paik Hospital, Busan, Korea.
- KMID: 2373819
- DOI: http://doi.org/10.3904/kjim.2014.353
Abstract
- No abstract available.
Keyword
MeSH Terms
-
Aged, 80 and over
Antimetabolites, Antineoplastic/*therapeutic use
Azacitidine/*analogs & derivatives/therapeutic use
Biomarkers, Tumor/analysis/genetics
Biopsy
Bone Marrow Examination
Cell Lineage
Female
Humans
Leukemia, Biphenotypic, Acute/*drug therapy/genetics/pathology
Phenotype
Remission Induction
Treatment Outcome
Antimetabolites, Antineoplastic
Azacitidine
Biomarkers, Tumor
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of CD19-Positive Mixed Phenotype Acute Leukemia with Blinatumomab
- Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
- Complex cytogenetics in a patient with mixed-phenotype acute leukemia
- Mixed-phenotype acute leukemia (MPAL) and beyond
- Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used
